Patent ID: 11891618
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The mouse of claim 8, wherein:
(i) the human TTR sequence at the genetically modified endogenous Ttr locus comprises a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 14;
(ii) the genetically modified endogenous Ttr locus encodes a protein comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 9;
(iii) the genetically modified endogenous Ttr locus comprises a coding sequence comprising a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 10; or
(iv) the genetically modified endogenous Ttr locus comprises a sequence at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence set forth in SEQ ID NO: 12 or 13.